**Supplementary Table S1.** Correlation between different treatment strategies and clinicopathological characteristics in advanced NSCLC patients

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| *n* (%) | 　 | Anlotinib | Immunotherapy | A+P combination therapy | c2 | *P* |
| Age (years) | 　 | 　 | 　 | 　 | 0.743  | 0.691  |
| 　 | < 60 | 73 (51.4%) | 29  | 17  | 27  | 　 | 　 |
| 　 | ≥60 | 69 (48.6%) | 26  | 13  | 30  | 　 | 　 |
| Gender | 　 | 　 | 　 | 　 | 2.112  | 0.348  |
| 　 | Male | 106 (74.6%) | 38  | 25  | 43  | 　 | 　 |
| 　 | Female | 36 (25.4%) | 17  | 5  | 14  | 　 | 　 |
| Smoking history | 　 | 　 | 　 | 　 | 2.380  | 0.304  |
| 　 | No | 44 (31.0%) | 21  | 7  | 16  | 　 | 　 |
| 　 | Yes | 98 (69.0%) | 34  | 23  | 41  | 　 | 　 |
| Surgery treatment | 　 | 　 | 　 | 　 | 0.906  | 0.636  |
| 　 | No | 120 (84.5%) | 46  | 27  | 47  | 　 | 　 |
| 　 | Yes | 22 (15.5%) | 9  | 3  | 10  | 　 | 　 |
| No. of prior systemic regimens | 　 | 　 | 　 | 　 | 6.606  | 0.158  |
| 　 | ≤2 | 46 (32.4%) | 15  | 8  | 23  | 　 | 　 |
| 　 | 3 | 68 (47.9%) | 30  | 18  | 20  | 　 | 　 |
| 　 | >3 | 28 (19.7%) | 10  | 4  | 14  | 　 | 　 |
| ECOG performance status | 　 | 　 | 　 | 　 | 0.595  | 0.743  |
| 　 | 0-1 | 124 (87.3%) | 49  | 25  | 50  | 　 | 　 |
| 　 | 2 | 18 (12.7%) | 6  | 5  | 7  | 　 | 　 |
| Histological subtype | 　 | 　 | 　 | 　 | 4.998  | 0.082  |
| 　 | Squamous cell carcinoma | 52 (36.6%) | 14  | 14  | 24  | 　 | 　 |
| 　 | Adenocarcinoma | 90 (63.4%) | 41  | 16  | 33  | 　 | 　 |
| TNM classification | 　 | 　 | 　 | 　 | 0.757  | 0.685  |
| 　 | III | 14 (9.9%) | 5  | 2  | 7  | 　 | 　 |
| 　 | IV | 128 (90.1%) | 50  | 28  | 50  | 　 | 　 |
| Tumor invasion | 　 | 　 | 　 | 　 | 8.709  | 0.191  |
| 　 | T1 | 2 (1.4%) | 2  | 0  | 0  | 　 | 　 |
| 　 | T2 | 7 (4.9%) | 5  | 0  | 2  | 　 | 　 |
| 　 | T3 | 22 (15.5%) | 8  | 3  | 11  | 　 | 　 |
| 　 | T4 | 111 (78.2%) | 40  | 27  | 44  | 　 | 　 |
| Lymph node metastasis | 　 | 　 | 　 | 　 | 3.157  | 0.789  |
| 　 | N0 | 1 (0.7%) | 0  | 0  | 1  | 　 | 　 |
| 　 | N1 | 3 (2.1%) | 2  | 1  | 0  | 　 | 　 |
| 　 | N2 | 18 (12.7%) | 7  | 3  | 8  | 　 | 　 |
| 　 | N3 | 120 (84.5%) | 46  | 27  | 47  | 　 | 　 |
| Distant metastasis | 　 | 　 | 　 | 　 | 0.757  | 0.685  |
| 　 | M0 | 14 (9.9%) | 5  | 2  | 7  | 　 | 　 |
| 　 | M1 | 128 (90.1%) | 50  | 28  | 50  | 　 | 　 |
| Metastatic sites | 　 | 　 | 　 | 　 | 2.196  | 0.334  |
| 　 | <3 | 70 (49.3%) | 26  | 12  | 32  | 　 | 　 |
| 　 | ≥3 | 72 (50.7%) | 29  | 18  | 25  | 　 | 　 |
| Brain metastasis | 　 | 　 | 　 | 　 | 6.118  | 0.047\* |
| 　 | No | 86 (60.6%) | 27  | 18  | 41  | 　 | 　 |
| 　 | Yes | 56 (39.4%) | 28  | 12  | 16  | 　 | 　 |
| Liver metastases | 　 | 　 | 　 | 　 | 4.466  | 0.107  |
| 　 | No | 94 (66.2%) | 39  | 15  | 40  | 　 | 　 |
| 　 | Yes | 48 (33.8%) | 16  | 15  | 17  | 　 | 　 |
| Bone metastases | 　 | 　 | 　 | 　 | 4.422  | 0.110  |
| 　 | No | 95 (66.9%) | 36  | 16  | 47  | 　 | 　 |
| 　 | Yes | 47 (33.1%) | 19  | 14  | 14  | 　 | 　 |
| PD-L1 TPS | 　 | 　 | 　 | 　 | 6.521  | 0.367  |
| 　 | <1% | 11 (7.7%) | 2  | 1  | 8  | 　 | 　 |
| 　 | 1-49% | 25 (17.6%) | 12  | 6  | 7  | 　 | 　 |
| 　 | ≥50% | 22 (15.5%) | 8  | 5  | 9  | 　 | 　 |
| 　 | Unknown | 84 (59.2%) | 33  | 18  | 33  | 　 | 　 |
| EGFR mutation status | 　 | 　 | 　 | 　 | 8.516  | 0.074  |
| 　 | Wild type (-) | 61 (43.0%) | 24  | 16  | 21  | 　 | 　 |
| 　 | Mutant (+) | 26 (18.3%) | 15  | 2  | 9  | 　 | 　 |
| 　 | Unknown | 55 (38.7%) | 16  | 12  | 27  | 　 | 　 |
| EGFR mutation subtype | 　 | 　 | 　 | 　 | 2.981  | 0.811  |
| 　 | 19del | 11 (42.3%) | 7  | 0  | 4  | 　 | 　 |
| 　 | 21L858R | 12 (46.2%) | 7  | 1  | 4  | 　 | 　 |
| 　 | T90M | 2 (7.7%) | 1  | 0  | 1  | 　 | 　 |
| 　 | Others | 1 (3.8%) | 0  | 0  | 1  | 　 | 　 |
| Previous thoracic radiation therapy | 　 | 　 | 　 | 　 | 1.423  | 0.491  |
| 　 | No | 104 (73.2%) | 41  | 24  | 39  | 　 | 　 |
| 　 | Yes | 38 (26.8%) | 14  | 6  | 18  | 　 | 　 |
| Previous antivascular drug therapy | 　 | 　 | 　 | 　 | 1.398  | 0.497  |
| 　 | No | 112 (78.9%) | 42  | 26  | 44  | 　 | 　 |
| 　 | Yes | 30 (21.1%) | 13  | 4  | 13  | 　 | 　 |
| \**P*< 0.05 | 　 | 　 | 　 | 　 | 　 | 　 |